Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (11-20 of 225) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancerCorey J Langer
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic OncologyCorey J Langer
The Oncologist|July 22, 2004
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax)Corey J Langer
Drugs & Aging|March 12, 2008
Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?Corey J Langer
Cancer|April 30, 2008
Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applicationsCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutationCorey J Langer
Clinical Lung Cancer|January 15, 2004
The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancerCorey J Langer
Expert Review of Anticancer Therapy|August 26, 2003
Role of targeted therapy in non-small cell lung cancer: hype or hope?Corey J Langer
Oncology (Williston Park, N.Y.)|July 31, 2003
The global role of irinotecan in the treatment of lung cancer: 2003 updateCorey J Langer
Clinical Lung Cancer|January 11, 2005
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanesCorey J Langer
Pageof 23

Showing results (11-20 of 225) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancerCorey J Langer
Clinical Advances in Hematology & Oncology : H&O|December 29, 2012
Highlights in NSCLC from the 2012 Chicago Multidisciplinary Symposium in Thoracic OncologyCorey J Langer
The Oncologist|July 22, 2004
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax)Corey J Langer
Drugs & Aging|March 12, 2008
Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?Corey J Langer
Cancer|April 30, 2008
Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applicationsCorey J Langer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutationCorey J Langer
Clinical Lung Cancer|January 15, 2004
The emerging role of gemcitabine in combination with radiation in locally advanced, unresectable non-small-cell lung cancerCorey J Langer
Expert Review of Anticancer Therapy|August 26, 2003
Role of targeted therapy in non-small cell lung cancer: hype or hope?Corey J Langer
Oncology (Williston Park, N.Y.)|July 31, 2003
The global role of irinotecan in the treatment of lung cancer: 2003 updateCorey J Langer
Clinical Lung Cancer|January 11, 2005
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanesCorey J Langer
Pageof 23